• Travere Therapeutics recently received a Notice of Allowance from the USPTO for a patent covering certain methods of using FILSPARI (sparsentan) to treat IgA nephropathy in the US, with protection expected to extend into October 2037 once issued and listed in the FDA’s Orange Book.
• This added layer of intellectual property protection around FILSPARI’s IgA nephropathy use could strengthen Travere’s competitive moat in rare kidney diseases, even as the product remains subject to strict REMS, safety monitoring, and prescribing restrictions.
• We’ll now examine how this extended FILSPARI patent protection in IgA nephropathy may influence Travere’s investment narrative and long-term outlook.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Travere Therapeutics Investment Narrative Recap

To own Travere, you need to believe FILSPARI can anchor a focused rare-kidney-disease franchise despite safety requirements, payer pressure, and ongoing losses. The new IgA nephropathy patent allowance modestly improves FILSPARI’s durability but does not change the near term focus on commercial execution and monitoring safety risks under the REMS program, which remain central to the story.

The most relevant recent milestone here is the April 2026 FDA approval of FILSPARI in FSGS, which broadened its labeled use beyond IgA nephropathy. Together, the FSGS approval and extended IgA nephropathy patent horizon frame FILSPARI as Travere’s core value driver while also concentrating regulatory, competition, and pricing risks in a single product family.

Yet, alongside this patent strength, investors should also be aware that...

Travere Therapeutics' narrative projects $1.2 billion revenue and $378.4 million earnings by 2029. This requires 32.5% yearly revenue growth and about a $424 million earnings increase from -$45.6 million today.

Uncover how Travere Therapeutics' forecasts yield a $53.57 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Travere could reach about US$1.5 billion in revenue and US$576.6 million in earnings by 2029, which is far more bullish than consensus. This new FILSPARI patent news may reinforce that upside view or cause a rethink of risks like pricing pressure and regulatory scrutiny, so it is worth comparing how your own expectations line up with such aggressive assumptions.

Explore 6 other fair value estimates on Travere Therapeutics - why the stock might be worth 31% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

No Opportunity In Travere Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.